Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Cancer Female 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Peripheral Blood Stem Cell Transplantation 2spartalizumab 1siltuximab 1sabatolimab 1ruxolitinib 1pelcitoclax 1fludarabine phosphate 1ethanolamine oleate 1durvalumab 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Pentostatin 1Pentetic Acid 1Ondansetron 1NIS-793 1Mycophenolic Acid 1Methotrexate 1In Situ Hybridization, Fluorescence 1Immunoglobulin G 1Immunoenzyme Techniques 1Flow Cytometry 1Filgrastim 1Ethanol 1Edetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Polycythemia Vera × durvalumab × Clear all
NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡